CSF/serum quotients for albumin and MASP-2 with individual CSF and serum concentrations of MASP-2 in controls and patients with barrier dysfunctions and the individual expected CSF MASP-2 and CSF MASP-2.
The complete set of protein data for CSF and serum of both groups (i.e., with and without a blood CSF barrier dysfunction). The corresponding CSF/serum concentration quotients of MASP-2 are shown as a function of the albumin quotient.
Steps to reproduce
CSF and serum samples were taken from patients of the Department of the Neurological University Hospital, Gottingen. All samples were taken for routine analysis, 13, 6, 8 indicated by diagnostic criteria with the written informed consent of the patients. After routine analysis, residual CSF and serum samples were stored at -80°C anonymously, according to the ethics committee of Aarhus University laboratories. From these residual CSF and serum samples, we selected retrospectively two groups for this study: 45 normal controls patients without organic brain disease with normal CSF and normal barrier function. Control patients were determined non-inflammatory disease to be normal according to clinical and imaging criteria, e.g. headache or non-inflammatory polyneuropathies, and according to their CSF and blood data (normal CSF leukocyte count and protein values), no oligoclonal IgG, age-related normal albumin quotient, normal blood leukocytes and serum C-reactive protein. In addition, the second group with 11 patients with barrier dysfunctions without intrathecal immune response but with increased Q Albumin, i.e. with a blood/CSF barrier dysfunction. Patients with non-inflammatory diseases but with blood/CSF barrier dysfunction given for an increase of CSF/serum albumin quotients (Q Albumin) as well as all other blood-derived CSF/serum protein quotients (QIgG, QIgA, QIgM) but without any intrathecal synthesis of IgG, IgA and IgM. These patients did not had oligoclonal IgG in CSF. Patients had spinal canal stenosis, spinal tumor or disc prolapse. They had normal CSF cell counts and typical findings of these diseases in electromyography, magnetic resonance and tomography. Method Cerebrospinal fluid was obtained by lumbar puncture and serum from blood was taken by venipuncture. Serum and CSF was stored frozen in aliquots at -80°C until analysis. Routine parameters such as albumin-, immunoglobulin- CSF/serum quotients, oligoclonal IgG, cell count, clinical and imaging criteria that were used to characterize the patient groups, were measured in the Neurochemistry Department of the University Hospital, Gottingen. CSF and serum albumin were quantified by immunochemical nephelometry with two-point or kinetic analysis (Wildemannet al. 2010). Serum MASP-2 levels were measured by commercial enzyme-linked immunosorbent assay (ELISA) kit (Hycult Biotech, Uden, the Netherlands) 14 CSFMASP-2 was quantify by the same method with undiluted CSF samples.